Aytu BioPharma Future Growth
Future criteria checks 3/6
Aytu BioPharma is forecast to grow earnings and revenue by 67.4% and 2.2% per annum respectively while EPS is expected to grow by 69.6% per annum.
Key information
67.4%
Earnings growth rate
69.6%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 2.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Feb 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2025 | 125 | 8 | 12 | 12 | 1 |
| 6/30/2024 | 124 | -1 | 7 | 6 | 2 |
| 6/30/2023 | 108 | -14 | N/A | -17 | 1 |
| 12/31/2022 | 106 | -78 | -28 | -28 | N/A |
| 9/30/2022 | 102 | -83 | -34 | -34 | N/A |
| 6/30/2022 | 97 | -110 | -29 | -29 | N/A |
| 3/31/2022 | 93 | -111 | -30 | -28 | N/A |
| 12/31/2021 | 82 | -84 | -30 | -28 | N/A |
| 9/30/2021 | 74 | -82 | -24 | -22 | N/A |
| 6/30/2021 | 66 | -58 | -28 | -26 | N/A |
| 3/31/2021 | 57 | -42 | -27 | -27 | N/A |
| 12/31/2020 | 52 | -22 | -30 | -30 | N/A |
| 9/30/2020 | 40 | -13 | -33 | -33 | N/A |
| 6/30/2020 | 28 | -14 | -28 | -28 | N/A |
| 3/31/2020 | 14 | -25 | -24 | -24 | N/A |
| 12/31/2019 | 9 | -24 | -16 | -16 | N/A |
| 9/30/2019 | 7 | -29 | -14 | -14 | N/A |
| 6/30/2019 | 7 | -27 | -14 | -14 | N/A |
| 3/31/2019 | 7 | -12 | -16 | -15 | N/A |
| 12/31/2018 | 5 | -10 | -17 | -16 | N/A |
| 9/30/2018 | 4 | -9 | -15 | -14 | N/A |
| 6/30/2018 | 4 | -10 | -16 | -16 | N/A |
| 3/31/2018 | 4 | -17 | -15 | -15 | N/A |
| 12/31/2017 | 4 | -20 | -17 | -13 | N/A |
| 9/30/2017 | 4 | -21 | -19 | -13 | N/A |
| 6/30/2017 | 3 | -23 | -20 | -14 | N/A |
| 3/31/2017 | 3 | -31 | -21 | -13 | N/A |
| 12/31/2016 | 3 | -33 | -17 | -13 | N/A |
| 9/30/2016 | 3 | -32 | N/A | -14 | N/A |
| 6/30/2016 | 3 | -28 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AY20 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: AY20 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AY20 is expected to become profitable in the next 3 years.
Revenue vs Market: AY20's revenue (2.2% per year) is forecast to grow slower than the German market (4.6% per year).
High Growth Revenue: AY20's revenue (2.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AY20's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/08 13:46 |
| End of Day Share Price | 2023/01/10 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aytu BioPharma, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jennifer Kim | Cantor Fitzgerald & Co. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Nazibur Rahman | Maxim Group |